NCT06090266View on ClinicalTrials.gov

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

February 1, 2027

Conditions
CancerTumor, SolidMalignant NeoplasmMetastatic CancerAdvanced Solid TumorCutaneous MelanomaNon-small Cell Lung Cancer
Interventions
DRUG

OR502

IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.

DRUG

Cemiplimab

IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Trial Locations (4)

22031

RECRUITING

NEXT Virginia, Fairfax

75039

RECRUITING

NEXT Dallas, Irving

78229

RECRUITING

NEXT Oncology, San Antonio

78758

RECRUITING

NEXT Austin, Austin

Sponsors

Lead Sponsor

OncoResponse, Inc.
All Listed Sponsors
lead

OncoResponse, Inc.

INDUSTRY

NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Biotech Hunter | Biotech Hunter